 |
 |
ABOUT US
MISSION / VISION
ABOUT US
The Center for Biomarkers in Imaging is an academic, non-profit organization dedicated to the identification, characterization and validation of biomarkers. Founded in April 2001, the Center is based within the Department of Radiology at the Massachusetts General Hospital. Located in downtown Boston, the hospital is a major teaching affiliate of Harvard Medical School. CBI has also joined forces with the Harvard-MIT Division of Health Sciences and Technology (HST), facilitating research collaborations and educational opportunities between CBI and HST, as well as the Harvard and MIT communities at large.
MISSION / VISION
The Center for Biomarkers in Imaging (CBI) at MGH and HST is a non-profit, academic organization dedicated to the identification, characterization and validation of image-related biomarkers, defined as anatomic, physiologic, biochemical, or molecular parameters associated with the presence and severity of specific disease states. Built on extensive imaging experience, the Center for Biomarkers in Imaging will gather, catalog, and maintain an extensive, easily accessible database on biomarkers, to be shared with academia, government and industry. Through this process, CBI will promote the application of biomarkers as pre-clinical and clinical endpoints in the evaluation of new drugs and medical devices, ultimately resulting in more accurate, timely and transparent regulatory decisions.
The Center for Biomarkers in Imaging draws on both MGH Radiology’s, as well as Harvard-MIT HST’s, extensive experience in working with industry, academia and the government to successfully employ imaging-related biomarkers in both the pre-clinical and clinical arenas. Examples may be found by selecting an area of experience below:
Biomarkers
Diseases
| BIOMARKERS |
| Biliary ductal dilatation |
Intra-arterial thrombus |
Neurotransmitter uptake and binding |
| Body fat composition |
Intravenous thrombus |
Osseous fusion |
| Bone marrow composition |
Lesion volume/brain |
Osseous metastases, presence of |
| Bone mineral density |
Lesion volume/colon |
Periarticular erosion |
| Cartilage volume |
Lesion volume/head and neck |
Pulmonary metastases, presence of |
| Cerebral diffusion/perfusion |
Lesion volume/liver |
Protein synthesis |
| Cerebral infarct size |
Lesion volume/lung |
Renal stones, presence of |
| CNS demyelination |
Lesion volume/pancreas |
Tissue perfusion |
| Endometrial thickness |
Lesion volume/ovarian |
Tumor metabolic activity |
| Fat content of bone marrow |
Liver tissue characterization |
Vertebral body height |
| Hydronephrosis |
Lymph node metastases, presence of |
|
| DISEASES |
| Arterial thrombus |
Glioblastoma multiforme |
Multiple Sclerosis |
| Biliary strictures |
Gynecological malignancy |
Obesity |
| Cholangitis |
Head and neck cancer |
Osteoporosis |
| Cholangiocarcinoma |
Hepatic hemangioma |
Ovarian cancer |
| Cholelithiasis |
Hepatocellular carcinoma |
Pancreatitis |
| Colon cancer |
Infection |
Pancreatic cancer |
| Deep venous thrombosis |
Ischemic stroke |
Parkinson’s Disease |
| Diabetes |
Lung cancer |
Prostate cancer |
| Focal nodular hyperplasia |
Lymphoma |
Rheumatoid arthritis |
| Focal splenic lesions |
Metastatic breast cancer |
Spinal fusion |
| Gaucher’s Disease |
Metastatic colon cancer |
Stroke |
|
 |
 |
|
|